Dr. Anthony Apicelli, M.D.

Claim this profile

Washington University School of Medicine

Studies Cancer
Studies Solid Tumors
4 reported clinical trials
9 drugs studied

Affiliated Hospitals

Image of trial facility.

Washington University School Of Medicine

Clinical Trials Anthony Apicelli, M.D. is currently running

Image of trial facility.

Proton Radiotherapy

for Palliative Cancer Care

Spatially fractionated radiotherapy (SFRT or GRID) addresses some limitations of traditional stereotactic body radiation therapy by relying on beam collimation to create high-dose "peaks" and intervening low-dose "valleys" throughout the target volume. Standard palliative radiotherapy regimens provide limited durability of response, and there are challenges with delivery to large tumors or in previously irradiated fields. In this study, Proton GRID radiotherapy will be used to deliver three-fraction palliative radiotherapy to patients with tumors needing palliative radiation. The safety and efficacy of this approach will be assessed. It is hypothesized that GRID is highly effective, immunogenic, and associated with low rates of toxicity.

Recruiting

1 award

N/A

Image of trial facility.

Radiation, Cisplatin, and Surgery

for Throat Cancer

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by the human papillomavirus (HPV) and are often cured with current therapy. However, patients treated with surgery followed by postoperative adjuvant chemotherapy and radiation therapy (POA(C)RT) still experience substantial morbidity. In this highly curable disease, current clinical research interest is focused on investigation of de-escalated therapy, with the goal to reduce treatment-related adverse events (AEs) while maintaining a low recurrence rate. In this study, patients with HPV-related OPSCC will undergo resection of the primary tumor site and involved/at-risk regional neck nodes. Based on the pathology report, patients will be assigned to: * Arm 1 (de-POACRT-42 Gy) * Arm 2A (de-POART-42 Gy) * Arm 2B (de-POART-37.8 Gy) * Arm 2C (de-POACRT-30 Gy). All patients with high-risk pathology will be assigned to Arm 1 whereas patients with intermediate-risk pathology will be randomized (1:1:1) to Arm 2A, Arm 2B, or Arm 2C. Patients with highest-risk pathology and low-risk pathology will be removed from the trial after surgery and will be advised to pursue standard of care options.

Recruiting

1 award

Phase 2

6 criteria

More about Anthony Apicelli, M.D.

Clinical Trial Related

6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Anthony Apicelli, M.D. has experience with

  • Radiation Therapy
  • Proton GRID Radiotherapy
  • Paclitaxel
  • Research Blood Draw
  • ADI PEG20
  • Ifosfamide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Anthony Apicelli, M.D. specialize in?

Is Anthony Apicelli, M.D. currently recruiting for clinical trials?

Are there any treatments that Anthony Apicelli, M.D. has studied deeply?

What is the best way to schedule an appointment with Anthony Apicelli, M.D.?

What is the office address of Anthony Apicelli, M.D.?

Is there any support for travel costs?